Exerkine Corporation is a biotech-pharmaceutical company dedicated to developing groundbreaking therapies for genetic and aging-associated diseases. Our team combines an in-depth understanding of exercise physiology with cutting-edge technology to create highly effective treatments. Our bioengineered exosome-based drug delivery technology is a major breakthrough in genetic disease treatment, surpassing the effectiveness of existing FDA-approved therapies.

We have seen remarkable results in preclinical trials targeting Lysosomal Storage Diseases, and are excited about the potential to address mitochondrial myopathies and neuromuscular disorders, among others. Furthermore, we have developed therapies based on Exerkines ™ that show promise in treating aging-associated diseases, including obesity, diabetes, cardiovascular diseases, and neurodegenerative diseases. We are committed to partnering with other organizations to accelerate clinical testing and commercialization, and to expanding the reach and impact of our intellectual property.

Our ultimate goal is to improve the lives of patients worldwide by revolutionizing the treatment of genetic and aging-related conditions